Mahana Therapeutics is a San Francisco–based developer of prescription digital therapeutics that deliver cognitive behavioral therapy (CBT) for chronic conditions. Its lead product, Mahana IBS, is an FDA‑cleared, prescription‑only digital therapeutic delivered via web and mobile apps and indicated as a three‑month CBT treatment for adults with IBS. Mahana IBS showed effectiveness in a 558‑patient clinical trial, with patients experiencing significant improvements in IBS symptom severity and daily functioning. The company plans to use new capital to launch Mahana IBS commercially and to accelerate development of several additional digital therapeutics for chronic health conditions. The app is available for iOS and Android and may be used alongside other IBS treatments. Mahana emphasizes expanding patient access to CBT where licensed clinicians are scarce.

Total raised

$61M

Funding rounds

1

Latest round

Series B

Latest activity

Aug 2021